Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized Study of Adjuvant Cretostimogene Grenadenorepvec Versus Observation for the Treatment of Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC) Following Transurethral Resection of Bladder Tumor (TURBT)

NCT06111235 is registered in ClinicalTrials.gov with CG Oncology, Inc. as lead sponsor.

NCT NCT06111235
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06111235 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized Study of Adjuvant Cretostimogene Grenadenorepvec Versus Observation for the Treatment of Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC) Following Transurethral Resection of Bladder Tumor (TURBT)
Lead sponsor
CG Oncology, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
December 14, 2023
Completion date
February 28, 2029
Enrollment
367 (actual)
Sites
95

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, non muscle invasive bladder cancer, urologic cancer, urothelial carcinoma